GLP-1 and Adiponectin: Effect of Weight Loss After Dietary Restriction and Gastric Bypass in Morbidly Obese Patients with Normal and Abnormal Glucose Metabolism

[1]  W. Malaisse,et al.  Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. , 2005, Journal of molecular endocrinology.

[2]  L. Arnes,et al.  Participation of Protein Kinases in the Stimulant Action of GLP-1 on 2-deoxy-D-glucose Uptake by Normal Rat Skeletal Muscle , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[3]  J. Holst,et al.  On the Physiology of GIP and GLP-1 , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[4]  Henry Buchwald,et al.  Bariatric surgery: a systematic review and meta-analysis. , 2004, JAMA.

[5]  D. Cummings,et al.  Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. , 2004, The Journal of clinical endocrinology and metabolism.

[6]  J. Holst,et al.  Incretins, insulin secretion and Type 2 diabetes mellitus , 2004, Diabetologia.

[7]  D. Drucker.  Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. , 2003, Endocrinology.

[8]  D. Drucker.  Enhancing incretin action for the treatment of type 2 diabetes. , 2003, Diabetes care.

[9]  P. Garcia-Lorda,et al.  Prevalence of Co-morbidities in Obese Patients before Bariatric Surgery: Effect of Race , 2003, Obesity surgery.

[10]  Shankuan Zhu,et al.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of internal medicine.

[11]  Michael B Wheeler,et al.  The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. , 2002, Diabetes.

[12]  W. Malaisse,et al.  Pancreatic and extrapancreatic effects of GLP-1. , 2002, Diabetes & metabolism.

[13]  H. Lodish,et al.  Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl–CoA carboxylase inhibition and AMP-activated protein kinase activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[15]  F. Greenway,et al.  Effects of obesity surgery on non-insulin-dependent diabetes mellitus. , 2002, Archives of surgery.

[16]  J. Egan,et al.  Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. , 2002, The Journal of clinical endocrinology and metabolism.

[17]  C. Bogardus,et al.  Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. , 2002, Diabetes.

[18]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[19]  T. Tai,et al.  Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. , 2001, The Journal of clinical endocrinology and metabolism.

[20]  I. Valverde,et al.  Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models , 2001, Endocrine.

[21]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[22]  Małgorzata Stańczyk,et al.  Revision of Failed Gastric Bypass to Distal Roux-en-Y Gastric Bypass: A Review of 65 Cases , 2001, Obesity surgery.

[23]  R. Walker,et al.  Diagnosing insulin resistance in the general population. , 2001, Diabetes care.

[24]  H. Lodish,et al.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  I. Valverde,et al.  Effect of GLP-1 on Lipid Metabolism in Human Adipocytes , 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[26]  GS Hotamisligil,et al.  Molecular mechanisms of insulin resistance and the role of the adipocyte , 2000, International Journal of Obesity.

[27]  S. Kihara,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[28]  S. Kihara,et al.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. , 2000, Blood.

[29]  S. Kihara,et al.  Genomic structure and mutations in adipose-specific gene, adiponectin , 2000, International Journal of Obesity.

[30]  H Wedel,et al.  Differentiated long-term effects of intentional weight loss on diabetes and hypertension. , 2000, Hypertension.

[31]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[32]  T Nakamura,et al.  An Adipocyte-Derived Plasma Protein, Adiponectin, Adheres to Injured Vascular Walls , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[33]  T Nakamura,et al.  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. , 1999, Circulation.

[34]  T. Funahashi,et al.  Molecular Mechanism of Metabolic Syndrome X: Contribution of Adipocytokines · Adipocyte‐derived Bioactive Substances , 1999, Annals of the New York Academy of Sciences.

[35]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[36]  I. Valverde,et al.  GLP-1 (7 - 36) Amide: Effects on Glucose Transport and Metabolism in Rat Adipose Tissue , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[37]  B. Spiegelman,et al.  AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.

[38]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[39]  Philipp E. Scherer,et al.  A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes (*) , 1995, The Journal of Biological Chemistry.

[40]  R. DeFronzo,et al.  Pathogenesis of NIDDM: A Balanced Overview , 1992, Diabetes Care.

[41]  I. Valverde,et al.  Lipolytic action of glucagon-like peptides in isolated rat adipocytes , 1992, Peptides.

[42]  G. Dohm,et al.  Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. , 1992, The American journal of clinical nutrition.

[43]  M. Walker,et al.  A comparison of measurements of lean body mass derived by bioelectrical impedance, skinfold thickness and total body potassium. A study in obese and non-obese normal subjects. , 1991, Scandinavian journal of clinical and laboratory investigation.

[44]  G A Colditz,et al.  Weight as a risk factor for clinical diabetes in women. , 1990, American journal of epidemiology.

[45]  L. Groop,et al.  Obesity and insulin resistance in humans: a dose-response study. , 1990, Metabolism: clinical and experimental.

[46]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[47]  Daniel Marin.  Resistencia a insulina e função da celula 'beta' : efeito da perda de peso apos bypass gastrico , 2007 .

[48]  P. Strobel,et al.  isolated rat adipocytes. , 2004 .

[49]  JA Potteiger,et al.  A comparison of methods for analyzing glucose and insulin areas under the curve following nine months of exercise in overweight adults , 2002, International Journal of Obesity.

[50]  W. Creutzfeldt.  The entero-insular axis in type 2 diabetes--incretins as therapeutic agents. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[51]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.